Vivo Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Vivo Capital’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-655,057	Closed	-$5.33M	–	45
2023 Q4	$5.33M	Hold	655,057	–	–	0.44%	35
2023 Q3	$2.98M	Hold	655,057	–	–	0.33%	42
2023 Q2	$4.61M	Hold	655,057	–	–	0.32%	38
2023 Q1	$4M	Hold	655,057	–	–	0.28%	36
2022 Q4	$4.19M	Hold	655,057	–	–	0.48%	35
2022 Q3	$6.28M	Hold	655,057	–	–	0.69%	35
2022 Q2	$7.23M	Hold	655,057	–	–	0.73%	29
2022 Q1	$10.9M	Buy	655,057 +354,057	+118%	+$5.48M	0.75%	28
2021 Q4	$5.75M	Buy	+301,000	New	+$6.63M	0.35%	45
2019 Q3	–	Sell	-1,600,000	Closed	-$39.2M	–	18
2019 Q2	$39.2M	Hold	1,600,000	–	–	3.68%	7
2019 Q1	$15.2M	Hold	1,600,000	–	–	1.52%	18
2018 Q4	$14.2M	Buy	+1,600,000	New	+$15.4M	1.81%	15

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vivo Capital's IOVA Position: Q1 2024 in Review

Vivo Capital sold out of Iovance Biotherapeutics (IOVA) in Q1 2024, closing a stake of 655,057 shares — an estimated $5.33M sold.

Vivo Capital first reported a position in IOVA in Q4 2018 and held it in 12 quarters. The position peaked at $39.2M in Q2 2019. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.

Vivo Capital reported no remaining Iovance Biotherapeutics position as of Q1 2024 after selling out during the quarter.
Vivo Capital sold 655,057 Iovance Biotherapeutics shares in Q1 2024, an estimated $5.33M.
Vivo Capital first reported a position in Iovance Biotherapeutics in Q4 2018 and held it in 12 quarters.
Vivo Capital's Iovance Biotherapeutics position peaked at $39.2M in Q2 2019.
273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.

Based on Vivo Capital's 13F filing for Q1 2024, filed 22 Apr 2024.